Objectif Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and requires significant investment. NeuroFGL will contribute to decrease these barriers through: (1) the clinical advancement of a promising novel regenerative therapy (FGLs) for neurological disorders, (2) hedging the clinical development by developing tests that enable early clinical assessments to be made, thereby maximising the chance that FGL and other neurogenerative therapies actually become developed to the benefit of patients and society; and (3) Selecting a target patient population with less variability and thereby easier to study – reducing and time resources needed, and increase predictability . FGLs is a promising and novel regenerative therapy being the clinical lead development candidate selected from a group of allosteric FGF-receptor modulators (referred to as FGL) mimicking NCAM. FGL has demonstrated positive effects in a number of in vivo models of neurodegeneration, e.g. beta-amyloid induced toxicity, global ischemia and chronic stress. The in vivo effects of FGL suggest a disease-modifying activity in several neurodegenerative disorders, such as neurogenesis. A phase I clinical study has demonstrated a FGL peptide to be well tolerated and safe. NeuroFGL will refine existing and develop new tests and techniques, that will at an early stage of the clinical development: (1) provide better information on the mechanisms of action (NCAM mimicking allosteric FGF recoter modulation) in man, (2) deliver translational effects seen between animal and man, (3) provide results earlier and cheaper, increasing the iteratiation and (4) select patients with conditions associated with less variability, e.g. patients with AD with a specific EEG or patients progressing to AD identified in patients with MCI. These developments will together provide a more robust basis for the development of FGLs, other drugs with a similar mechanism of action and other therapies for neurodegenerative disorders. Champ scientifique natural sciencesbiological sciencesneurobiologymedical and health sciencesbasic medicineneurologydementiaalzheimernatural sciencesbiological sciencesbiochemistrybiomoleculesmedical and health sciencesbasic medicineneurologystroke Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH.2011.1.4-1 - Regenerative medicine clinical trials Appel à propositions FP7-HEALTH-2011-two-stage Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur KOBENHAVNS UNIVERSITET Contribution de l’UE € 240 806,15 Adresse NORREGADE 10 1165 Kobenhavn Danemark Voir sur la carte Région Danmark Hovedstaden Byen København Type d’activité Higher or Secondary Education Establishments Contact administratif Ivan Kristoffersen (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (6) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire ENKAM PHARMACEUTICALS A/S Danemark Contribution de l’UE € 3 985 513,85 Adresse Fruebjergvej, 3 2100 COPENHAGEN Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Morten Albrechtsen (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée FORENAP PHARMA Participation terminée France Contribution de l’UE Aucune donnée Adresse RUE DU 4EME SPAHIS MAROCAINS 27 68250 ROUFFACH Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Sandra Werner (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée H. LUNDBECK AS Danemark Contribution de l’UE € 39 999,00 Adresse OTTILIAVEJ 7-9 2500 Valby Voir sur la carte Région Danmark Hovedstaden Byen København Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Jan Egebjerg (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Qualissima France Contribution de l’UE € 1 100 500,00 Adresse Rue Clapier 13001 Marseille Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Severine Pitel (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée KLINIKUM DER UNIVERSITAET ZU KOELN Allemagne Contribution de l’UE € 394 674,00 Adresse Kerpener Strasse 62 50937 Koeln Voir sur la carte Région Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt Type d’activité Higher or Secondary Education Establishments Contact administratif Jutta Landvogt (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée NARODNI USTAV DUSEVNIHO ZDRAVI Tchéquie Contribution de l’UE € 217 242,00 Adresse TOPOLOVA 748 250 67 Klecany Voir sur la carte Région Česko Střední Čechy Středočeský kraj Type d’activité Research Organisations Contact administratif Alexandr Borovicka (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée